Liraglutide: An injectable option for the management of obesity

Annals of Pharmacotherapy

Volumn 49, Issue 8, 2015, Pages 938-944

  Clements, Jennifer N ^a   Shealy, Kayce M ^a  

^a PRESBYTERIAN COLLEGE   (United States)

Author keywords

Ambulatory care; Clinical pharmacy; Clinical practice guidelines; Endocrinology; Obesity

Indexed keywords

LIRAGLUTIDE; METFORMIN; PLACEBO; TETRAHYDROLIPSTATIN; ANTIOBESITY AGENT; LACTONE;

ARTICLE; BODY WEIGHT MANAGEMENT; CLINICAL EFFECTIVENESS; CONTROLLED CLINICAL TRIAL (TOPIC); HUMAN; IMPAIRED GLUCOSE TOLERANCE; MULTICENTER STUDY (TOPIC); OBESITY; OVARY POLYCYSTIC DISEASE; PATIENT SAFETY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT RESPONSE; WEIGHT REDUCTION; COMPLICATION; FEMALE; LIFESTYLE; SUBCUTANEOUS DRUG ADMINISTRATION;

ANTI-OBESITY AGENTS; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; LACTONES; LIFE STYLE; LIRAGLUTIDE; OBESITY; POLYCYSTIC OVARY SYNDROME; PREDIABETIC STATE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84943194818     PISSN: 10600280     EISSN: 15426270     Source Type: Journal    
DOI: 10.1177/1060028015586806     Document Type: Article

References (33)

1. Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of childhood and adult obesity in the United States, 2011-2012. JAMA. 2014;311:806-814.
2. Centers for Disease Control and Prevention. Overweight and obesity: obesity prevalence maps. http://www.cdc.gov/obesity/data/prevalence-maps.html. Accessed March 8, 2015.
3. Finkelstein EA, Trogdon JG, Cohen JW, Dietz W. Annual medical spending attributable to obesity: payer-and-service specific estimates. Health Aff (Millwood). 2009;28:w822-w831.
4. Apovian CM, Aronne LJ, Bessesen DH, et al. Pharmacological management of obesity: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2015;100: 342-362.
5. Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/ TOS guideline for the management of overweight and obesity in adults. J Am Coll Cardiol. 2014;63:2985-3023.
6. Seger JC, Horn DB, Westman EC, et al. Obesity algorithm, presented by the American Society of Bariatric Physicians, 2014-2015. http://www.obesityalgorithm.org. Accessed March 6, 2015.
7. Garber AJ, Abrahamson MJ, Barzilay JI, et al. AACE Comprehensive Diabetes Management Algorithm. Endocr Pract. 2013;19:327-336.
8. Saxenda [package insert]. Plainsboro, NJ: Novo Nordisk; 2015.
9. Victoza [package insert]. Plainsboro, NJ: Novo Nordisk; 2015.
10. Neumiller JJ, Campbell RK. Liraglutide: a once-daily incretin mimetic for the treatment of type 2 diabetes mellitus. Ann Pharmacother. 2009;43:1433-1444.
11. Montanya E, Sesti G. A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon- like peptide 1 analogue, in the treatment of type 2 diabetes mellitus. Clin Ther. 2009;31:2472-2488.
12. Bode B. An overview of the pharmacokinetics, efficacy and safety of liraglutide. Diabetes Res Clin Pract. 2012;97:27-42.
13. Jacobsen LV, Hindsberger C, Robson R, Zdravkovic M. Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide. Br J Clin Pharmacol. 2009;68:898-905.
14. Marre M, Shaw J, Brandle M, et al. Liraglutide, a once daily human GLP-1 analog, added to a sulphoflurea (SU) offers significantly better glycemic control and favorable weight change compared with rosiglitazone and SU combination therapy in subjects with type 2 diabetes (abstract 13-OR). Diabetes. 2008;57:A4.
15. Nauck M, Frid A, Hermansen K, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin in type 2 diabetes mellitus (LEAD-2 Met). Diabetes Care. 2009;32:84-90.
16. Garber A, Henry R, Ratner R, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomized, 52-week, phase III, double-blind, parallel- treatment trial. Lancet. 2009;373:473-481.
17. Zinman B, Gerich J, Buse J, et al. Effect of the GLP-1 analogue liraglutide on glycaemic control and weight reduction in patients on metformin and rosiglitazone: a randomised double- blind placebo controlled trial [abstract 898]. Diabetologia. 2008;51:S359.
18. Russell-Jones D, Vaag A, Schmitz O, et al. Significantly better glycemic control and weight reduction with liraglutide, a once-daily human GLP-1 analog, compared with insulin glargine: all as add-on to metformin and sulfonylurea in type 2 diabetes [abstract 536-P]. Diabetes. 2008;57:A536-P.
19. Food and Drug Administration. Guidance for industry: developing products for weight management (draft guidance). http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071612.pdf. Accessed March 10, 2015.
20. Astrup A, Rossner S, Gaal LV, et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind placebocontrolled study. Lancet. 2009;374:1606-1616.
21. Astrup A, Carraro R, Finer N, et al. Safety, tolerability, and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes. 2012;36:843-854.
22. Wadden TA, Hollander P, Klein S, et al. Weight maintenance and additional weight loss with liraglutide after low-calorieinduced weight loss: the SCALE Maintenance randomized study. Int J Obes. 2013;37:1443-1451.
23. Novo Nordisk. Novo Nordisk company announcement. http://novonordisk.com/include/asp/exe_news_attachment.asp?sAttachmentGUID=872441E7-92CB-4A08-9BD7-EF262E9C797B. Accessed March 10, 2015.
24. Kim SH, Abbasi F, Lamendola C, et al. Benefits of liraglutide treatment in overweight and obese older individuals with prediabetes. Diabetes Care. 2013;36:3276-3282.
25. Sever MJ, Kocjan T, Pfeifer M, et al. Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin. Eur J Endocrinol. 2014;170:451-459.
26. Smith SR, Weissman NJ, Anderson CM, et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med. 2010;363:245-256.
27. Fidler MC, Sanchez M, Raether B, et al. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J Clin Enocrinol Metab. 211;96:3067-3077.
28. Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomized, placebo-controlled, phase 3 trial. Lancet. 2011;377:1341-1352.
29. Allison DB, Gadde KM, Garvey WT, et al. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity. 2012;20:330-342.
30. Greenway FL, Fujioka K, Plodkowski RA, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomized, double-blind, placebo- controlled, phase 3 trial. Lancet. 2010;376:595-605.
31. Apovian CM, Aronne L, Rubino D, et al. A randomized, phase 3 trial of naltrexone SR on weight and obesity-related risk factors (COR-II). Obesity. 2013;21:935-943.
32. Lean MEJ, Carraro R, Finer N, et al. Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults. Int J Obes. 2014;38:689-697.
33. Jensen T, Zawadzki S. Novo launches Saxenda in U.S., sees more launches in 2015. http://www.reuters.com/article/2015/ 04/22/us-novonordisk-saxenda-idUSKBN0ND1KX20150422. Accessed April 23, 2015.